Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Jun 23:33:155-160.
doi: 10.1016/j.jpra.2022.06.003. eCollection 2022 Sep.

Cemiplimab and Cutaneous Squamous Cell Carcinoma: From Bench to Bedside

D T Goodman  1
Affiliations
Review

Cemiplimab and Cutaneous Squamous Cell Carcinoma: From Bench to Bedside

D T Goodman. JPRAS Open. .

Abstract

Non-melanoma skin cancers (NMSCs) are the most common cancer in fair-skinned individuals with basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) being the most common subtype. While BCC has historically been the most common NMSC, SCC is increasing in incidence relative to BCC. SCC has a very poor prognosis with advanced local infiltration or when it achieves a metastatic state with around 50% of patients with locally advanced disease relapsing with an average overall survival of 10-13 months for patients with recurrent or metastatic disease. The pathogenesis of cutaneous SCC (cSCC) is multifactorial, and many studies have also described in detail the strong link between tumour apoptosis, DNA repair mechanism deficiencies, and developing cSCC. Patients with TP53 mutations are more susceptible to develop cSCC, thus highlighting the importance of cell cycle regulation and also pointing towards the potential therapeutic targets within. This review illustrates the role of the programmed death receptor-1 (PD-1) inhibitor cemiplimab in treating advanced and metastatic cSCC not suitable to surgical excision and describes its development in the context of the translational research paradigm from preclinical studies to its licenced implementation in clinical care and beyond.

Keywords: Cemiplimab; PD-1 inhibitor; Squamous cell carcinoma; Translational medicine.

PubMed Disclaimer

Conflict of interest statement

None declared

References

    1. Lomas A, Leonardi-Bee J, Bath-Hextall F. A systematic review of worldwide incidence of nonmelanoma skin cancer. Br J Dermatol. 2012;166(5):1069–1080. doi: 10.1111/j.1365-2133.2012.10830.x. - DOI - PubMed
    1. Rogers HW, Weinstock MA, Feldman SR, Coldiron BM. Incidence Estimate of Nonmelanoma Skin Cancer (Keratinocyte Carcinomas) in the U.S. Population, 2012. JAMA Dermatol. 2015;151(10):1081–1086. doi: 10.1001/jamadermatol.2015.1187. - DOI - PubMed
    1. Stratigos A, Garbe C, Lebbe C, Malvehy J, del Marmol V, Pehamberger H, Peris K, Becker JC, Zalaudek I, Saiag P, Middleton MR, Bastholt L, Testori A, Grob JJ. Diagnosis and treatment of invasive squamous cell carcinoma of the skin: European consensus-based interdisciplinary guideline. Eur J Cancer. 2015;51(14):1989–2007. doi: 10.1016/j.ejca.2015.06.110. - DOI - PubMed
    1. Kauvar AN, Arpey CJ, Hruza G, Olbricht SM, Bennett R, Mahmoud BH. Consensus for Nonmelanoma Skin Cancer Treatment, Part II: Squamous Cell Carcinoma, Including a Cost Analysis of Treatment Methods. Dermatol Surg. 2015;41(11):1214–1240. doi: 10.1097/dss.0000000000000478. - DOI - PubMed
    1. Administration FaD (2019) FDA approves cemiplimab-rwlc for metastatic or locally advanced cutaneous squamous cell carcinoma. https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-cemi.... Accessed April 14, 2021